XML 61 R47.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Research and License Agreements - Additional Information (Detail) | 1 Months Ended | 3 Months Ended | 12 Months Ended | 18 Months Ended
--- | --- | --- | --- | ---
Feb. 29, 2016 USD ($) | Aug. 31, 2015 USD ($) | Nov. 30, 2014 USD ($) item | May 31, 2014 USD ($) | Oct. 31, 2011 USD ($) item | Feb. 29, 2004 | Mar. 31, 2013 USD ($) | Dec. 31, 2011 USD ($) | Dec. 31, 2016 USD ($) | Dec. 31, 2015 USD ($) | Dec. 31, 2014 USD ($) | Dec. 31, 2012 USD ($) | Mar. 31, 2013
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone license fee liability |  |  |  |  |  |  |  |  |  | $ 2,000,000 |  |  |
Research and Development Expense |  |  |  |  |  |  |  |  | $ 23,281,820 | 25,050,179 | $ 19,571,073 |  |
License Agreement | Pfizer |  |  |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone revenue |  | $ 20,000,000 |  | $ 15,000,000 |  |  |  |  | 0 | 20,000,000 | $ 15,000,000 |  |
License Agreement | Pfizer | Up-Front Payment Arrangement |  |  |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  | $ 22,500,000 |  |  |  |  |  |  |  |
Upfront payment revenue recognized |  |  |  |  |  |  | $ 22,500,000 | $ 22,500,000 |  |  |  | $ 22,500,000 |
Recognition period of up-front payment |  |  |  |  |  |  |  |  |  |  |  |  | 1 year 6 months
License Agreement | Uni Quest Pty Limited |  |  |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Number of method-of-use patents under exclusive rights license agreement | item |  |  | 2 |  |  |  |  |  |  |  |  |  |
Milestone payment obligation |  |  | $ 2,000,000 |  |  |  |  |  |  |  |  |  |
License upfront fees |  |  | $ 20,000 |  |  |  |  |  |  |  |  |  |
Research and Development Expense |  |  |  |  |  |  |  |  | 0 | 0 |  |  |
Research Services Agreement | University Of Basel |  |  |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty payment due against license fees received (as a percent) |  |  |  |  |  | 10.00% |  |  |  |  |  |  |
Milestone license fee liability |  |  |  |  |  |  |  |  | $ 0 | $ 2,000,000 |  |  |
Payment of milestone liability | $ 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Achievement Of Specified Development Milestone | License Agreement | Pfizer |  |  |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Number of indications | item |  |  |  |  | 2 |  |  |  |  |  |  |  |
Achievement Of Specified Development Milestone | License Agreement | Pfizer | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments |  |  |  |  | $ 115,000,000 |  |  |  |  |  |  |  |
Achievement Of Specified Regulatory Milestone | License Agreement | Pfizer |  |  |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Number of indications | item |  |  |  |  | 2 |  |  |  |  |  |  |  |
Achievement Of Specified Regulatory Milestone | License Agreement | Pfizer | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments |  |  |  |  | $ 70,000,000 |  |  |  |  |  |  |  |
Achievement Of Specified Levels Of Annual Net Sales Of Licensed Products | License Agreement | Pfizer | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Research and License Agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments |  |  |  |  | $ 135,000,000 |  |  |  |  |  |  |  |

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for license and milestone fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References No definition available. + Details
Name: | glyc_AccruedLicenseAndMilestoneFees
Namespace Prefix: | glyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | glyc_ArrangementsAndNonarrangementTransactionsLineItems
Namespace Prefix: | glyc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of indications that trigger payment of milestones under the agreement. + References No definition available. + Details
Name: | glyc_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement
Namespace Prefix: | glyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of method-of-use patent applications secured by exclusive rights under a worldwide license agreement. + References No definition available. + Details
Name: | glyc_NumberOfMethodOfUsePatentApplicationsUnderExclusiveRightsAgreement
Namespace Prefix: | glyc_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the potential payment that may be received upon achievement of specified milestones per agreement. + References No definition available. + Details
Name: | glyc_PotentialPaymentForAchievementOfSpecifiedMilestones
Namespace Prefix: | glyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash inflow (outflow) related to contingent consideration receivable or payable. + References No definition available. + Details
Name: | glyc_ProceedsFromPaymentsForContingentConsiderationOperatingActivities
Namespace Prefix: | glyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the royalty commitment due as a percent of the milestone payments received under licensing arrangement. + References No definition available. + Details
Name: | glyc_RoyaltyCommitmentDueAgainstLicenseFeesReceivedAsPercent
Namespace Prefix: | glyc_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period of time over which the up-front payment received was recognized as revenue. + References No definition available. + Details
Name: | glyc_UpfrontPaymentRecognitionPeriod
Namespace Prefix: | glyc_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments. + References No definition available. + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenueAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=glyc_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=glyc_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=glyc_UniQuestPtyLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=glyc_ResearchServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=glyc_UniversityOfBaselMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedDevelopmentMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedRegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=glyc_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |